8-K: Merck Reports Strong Q2 2026 Sales, Advances Pipeline

Merck & Co., Inc. announced second-quarter 2026 financial results, highlighting $16.6 billion in worldwide sales with 5% growth, driven by oncology and animal health, alongside key regulatory approvals and clinical milestones.

Summary

• Merck & Co., Inc. reported second-quarter 2026 worldwide sales of $16.6 billion, a 5% increase (4% excluding foreign exchange).
• GAAP loss per share was $0.54, and non-GAAP loss per share was $0.13, both impacted by a $2.31 per share charge for the acquisition of Terns Pharmaceuticals.
• KEYTRUDA/KEYTRUDA QLEX sales reached $8.4 billion, showing 5% growth, with KEYTRUDA QLEX contributing $463 million.
• WINREVAIR sales grew significantly by 75% to $588 million.
• Animal Health sales increased by 8% to $1.8 billion.
• The company received FDA approval for LIPFENDRA (enlicitide), an oral PCSK9 inhibitor.
• Positive Phase 3 data was announced for sacituzumab tirumotecan in endometrial cancer and for an investigational oral HIV treatment regimen (Islatravir and Lenacapavir).
• The full-year 2026 sales outlook was narrowed and raised to $66.3 billion $67.3 billion, while the non-GAAP EPS outlook was lowered to $2.66 $2.76 due to acquisition-related charges.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a generally positive report, with strong sales growth and significant pipeline advancements, though the reported GAAP loss per share due to acquisition costs tempers the overall sentiment.

Positives

• Total worldwide sales grew 5% to $16.6 billion.
• KEYTRUDA/KEYTRUDA QLEX sales increased 5% to $8.4 billion, driven by strong uptake in earlier-stage indications.
• WINREVAIR sales showed substantial growth of 75% to $588 million.
• Animal Health sales increased 8% to $1.8 billion.
• FDA approval for LIPFENDRA (enlicitide), a new oral PCSK9 inhibitor, marks a significant advancement in cardiometabolic disease.
• Positive Phase 3 results for sacituzumab tirumotecan in endometrial cancer and for the investigational oral HIV treatment regimen (Islatravir and Lenacapavir) highlight pipeline strength.
• The full-year worldwide sales outlook was raised to a range of $66.3 billion to $67.3 billion.

Negatives

• Reported a GAAP loss per share of $0.54 and a non-GAAP loss per share of $0.13 for the second quarter of 2026.
• Both GAAP and non-GAAP loss per share were significantly impacted by a $2.31 per share charge related to the acquisition of Terns Pharmaceuticals.
• Full-year 2026 non-GAAP EPS outlook was lowered to $2.66 $2.76, down from $5.04 $5.16, due to substantial acquisition-related charges.
• R&D expenses increased significantly to $9.7 billion from $4.0 billion, largely due to the Terns acquisition charge.
• GAAP gross margin decreased to 73.5% from 77.5%, primarily due to higher amortization of intangible assets and inventory write-downs.
• Non-GAAP effective income tax rate increased significantly to 160.3% from 15.0% in the prior year quarter, impacted by acquisition charges.

Risks

• General industry conditions and competition.
• General economic factors, including interest rate and currency exchange rate fluctuations.
• Impact of pharmaceutical industry regulation and health care legislation.
• Global trends toward health care cost containment.
• Technological advances, new products and patents attained by competitors.
• Challenges inherent in new product development, including obtaining regulatory approval.
• Manufacturing difficulties or delays.
• Financial instability of international economies and sovereign risk.

Future Outlook

The company has narrowed and raised its full-year 2026 worldwide sales outlook to be between $66.3 billion and $67.3 billion. The non-GAAP EPS outlook has been lowered to a range of $2.66 to $2.76, which includes significant one-time charges related to the acquisitions of Cidara Therapeutics and Terns Pharmaceuticals, as well as financing costs for the Terns acquisition and advancement of MK-4208.

Management Comments

• "We continued to make substantial progress across our business this quarter, driven by strong execution and growing contributions from new product launches," said Robert M. Davis, chairman and chief executive officer.
• "The FDA approval of LIPFENDRA is an exciting moment for our company and for patients, marking the latest milestone in our nearly 70-year legacy in cardiovascular disease."
• "Together with key regulatory and clinical advances across oncology, HIV and immunology, this achievement reflects the strength of our pipeline and portfolio transformation as we bring forward the next wave of innovation."
• "I am confident in the ongoing execution of our strategy as we deliver for patients and further enhance our long-term growth trajectory."

Industry Context

StockSavvy.ai notes that Merck's performance aligns with broader trends in the pharmaceutical industry, particularly the strong demand for oncology treatments like KEYTRUDA and the continued investment in pipeline development for significant unmet medical needs such as HIV and cardiovascular diseases. The company's strategic acquisitions, like Terns Pharmaceuticals, underscore the industry's focus on consolidating innovative assets.

Comparison to Industry Standards

• Merck's KEYTRUDA sales growth of 5% is robust in the competitive oncology market, though some competitors may see higher percentage growth from smaller bases or newer entrants.
• The 75% growth for WINREVAIR indicates strong market penetration for a newer product, potentially outperforming industry averages for new drug launches.
• The significant increase in R&D spending to $9.7 billion reflects a substantial investment level, which is characteristic of leading biopharmaceutical companies aiming to maintain a competitive pipeline, though the magnitude is amplified by acquisition costs.
• The FDA approval of LIPFENDRA, a once-daily oral PCSK9 inhibitor, positions Merck to compete in the growing cardiovascular market, where other players like Amgen (Repatha) and Novartis (Leqvio) also have offerings.

Stakeholder Impact

• Shareholders: The lowered non-GAAP EPS outlook and reported GAAP loss per share may negatively impact short-term investor sentiment, despite strong sales growth and pipeline progress.
• Employees: Increased R&D and SG&A expenses, partly due to acquisitions, could signal continued investment in innovation and operations, potentially benefiting employees through growth opportunities.
• Customers (Patients): FDA approvals for LIPFENDRA and advancements in oncology and HIV treatments offer new therapeutic options, positively impacting patient care.
• Suppliers: Increased sales and R&D activities may lead to higher demand for raw materials and services from suppliers.

Next Steps

• Continue to advance the broad and diverse pipeline with key regulatory and clinical milestones.
• Focus on the uptake of new product launches such as WINREVAIR.
• Execute on the strategy to deliver for patients and enhance long-term growth trajectory.
• Hold an Oncology Investor Event on October 26, 2026, to provide an update on the oncology strategy and program.

Key Dates

Recommendation

While Merck demonstrates strong sales growth and a robust pipeline with key regulatory approvals, the significant acquisition-related charges leading to a reported loss per share and a substantially lowered full-year EPS outlook warrant a cautious approach. The long-term potential remains, but the immediate financial impact of these charges suggests holding the stock until the integration and financial normalization become clearer.

Keywords

pharmaceuticals, oncology, KEYTRUDA, animal health, HIV, vaccines, cardiovascular, clinical trials